Document Detail


Recurrence of venous thromboembolism in patients with familial thrombophilia.
MedLine Citation:
PMID:  9342999     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Treatment of patients with deep vein thrombosis and an antithrombin or protein C or S deficiency is based on case reports and personal experience. OBJECTIVE: To systematically assess the risk for recurrence of venous thromboembolism after a first episode in patients with these deficiencies, a literature review and retrospective family cohort study were performed. METHODS: For the literature review, the annual incidence of a first recurrent venous thromboembolism was assessed for each deficiency by dividing the number of venous thromboembolic events by the number of years at risk. For the family cohort study, 1- and 5-year cumulative incidences of first recurrence were calculated based on medical histories taken in relatives of consecutive patients in whom venous thromboembolism and a deficiency were diagnosed. RESULTS: For the literature review, the annual incidence of a first recurrent venous thromboembolism in patients with antithrombin or protein S deficiency ranged from 13% to 17% and 14% to 16%, respectively. For the family cohort study, the 1- and 5-year cumulative incidences of recurrent venous thromboembolism were 10% (95% confidence interval, 1%-19%) and 23% (95% confidence interval, 10%-36%), respectively. Warfarin sodium (Coumadin) prophylaxis was associated with 2 venous thromboembolic events in 141 years at risk (1.4% per year), in contrast with 19 events in 709 years at risk (2.7% per year) without prophylaxis (difference, -1.3%; 95% confidence interval, -3.5% to 1.0%). CONCLUSIONS: The annual incidence of recurrent venous thromboembolism is high during the first years following a first episode, but seems to decline thereafter. Therefore, our results challenge current practice of prescribing lifelong warfarin therapy after a first or second episode of venous thromboembolism in patients with antithrombin or protein C or S deficiency.
Authors:
A G van den Belt; B J Sanson; P Simioni; P Prandoni; H R Büller; A Girolami; M H Prins
Related Documents :
15316429 - Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systemat...
7086489 - Myopathy induced by epsilon-aminocaproic acid. case report.
19020209 - Transcatheter arterial embolization in the emergency department for hemodynamic instabi...
17222109 - Prevention of deep venous thrombosis and pulmonary embolism following stroke: a systema...
11750969 - Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administra...
2804589 - Randomized study of adjusted versus fixed low dose heparin prophylaxis of deep vein thr...
23076459 - Argon plasma coagulation is safe and effective for treating smaller gastric lesions wit...
17888209 - Radiographic progression of rheumatoid arthritis in patients from the czech national re...
15934439 - Very early development of steroid-associated osteonecrosis of femoral head in systemic ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Archives of internal medicine     Volume:  157     ISSN:  0003-9926     ISO Abbreviation:  Arch. Intern. Med.     Publication Date:  1997 Oct 
Date Detail:
Created Date:  1997-11-18     Completed Date:  1997-11-18     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0372440     Medline TA:  Arch Intern Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2227-32     Citation Subset:  AIM; IM    
Affiliation:
Department of Clinical Epidemiology and Biostatistics, Academic Medical Centre, University of Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / therapeutic use
Antithrombin III Deficiency
Cohort Studies
Humans
Incidence
Protein C Deficiency
Protein S Deficiency
Recurrence
Thromboembolism / blood,  genetics*,  prevention & control
Thrombophilia / blood,  complications*,  drug therapy,  genetics
Chemical
Reg. No./Substance:
0/Anticoagulants
Comments/Corrections
Comment In:
Arch Intern Med. 1997 Oct 27;157(19):2174-7   [PMID:  9342993 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Stress management and exercise training in cardiac patients with myocardial ischemia. Effects on pro...
Next Document:  Impact of age on the severity, course, and complications of alcohol withdrawal.